NcRuPAR Inhibits Gastric Cancer Progression by Down-regulating Protease-activated Receptor-1

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2014 May 13

PMID 24817013

Citations 25

Authors

Long Liu

Bing Yan

Zhihui Yang

Xiaodong Zhang

Qunhao Gu

XiaoQiang Yue

Affiliations

Soon will be listed here.

Abstract

ncRuPAR is a newly discovered long noncoding RNA molecule that can upregulate protease-activated receptor-1 (PAR-1) during embryonic growth; however, its role in cancer has not been elucidated. Here, we conducted a study to investigate the role of ncRuPAR in gastric cancer. Significant downregulation of ncRuPAR was detected in gastric cancer tissues compared with paired adjacent nontumor tissues; however, both PAR-1 and vascular endothelial growth factor (VEGF) messenger RNA (mRNA) levels were significantly higher in cancerous tissues compared with adjacent normal tissues. Additionally, the expression level of ncRuPAR was found to be significantly correlated with tumor invasion depth, lymph node metastasis, distant metastasis, tumor size, and tumor-nodes-metastasis (TNM) stage and inversely associated with the mRNA levels and extent (E) × intensity (I) scores of PAR-1 and VEGF. The protein level of PAR-1 was significantly correlated with tumor size only, while the VEGF protein level was significantly correlated with invasion depth and tumor size. The area under the receiver operating characteristic (ROC) curve of ncRuPAR was 0.84 (95 % CI 0.79-0.88) at a cutoff value of 4.97; ncRuPAR had a sensitivity of 88.41 %, a specificity of 73.91 %, and an accuracy of 81.16 % for the prediction of gastric cancer. These results suggest that ncRuPAR inhibits gastric cancer development, and its underlying mechanism involves the inhibition of PAR-1. In addition, ncRuPAR could be regarded as a marker for gastric cancer in the future.

Citing Articles

lncRNA TCONS_00251376 promotes the proliferation and migration of gastric cancer cell through upregulating ETV1.

Ren D, Zhao F, Li J, Guo X, Ma X, Zheng Y Cancer Innov. 2024; 4(1):e156.

PMID: 39668941 PMC: 11636580. DOI: 10.1002/cai2.156.

miR-122-IGF-1R signaling allied through the dysregulated lncRNA expression in gastric carcinoma.

Kadry M Toxicol Rep. 2024; 12:338-344.

PMID: 38544957 PMC: 10965482. DOI: 10.1016/j.toxrep.2024.03.005.

Computational identification and clinical validation of a novel risk signature based on coagulation-related lncRNAs for predicting prognosis, immunotherapy response, and chemosensitivity in colorectal cancer patients.

Zhang F, Zhang R, Zong J, Hou Y, Zhou M, Yan Z Front Immunol. 2023; 14:1279789.

PMID: 37928532 PMC: 10620970. DOI: 10.3389/fimmu.2023.1279789.

The Intricate Role of Non-Coding RNAs in Sepsis-Associated Disseminated Intravascular Coagulation.

Canovas-Cervera I, Nacher-Sendra E, Osca-Verdegal R, Dolz-Andres E, Beltran-Garcia J, Rodriguez-Gimillo M Int J Mol Sci. 2023; 24(3).

PMID: 36768905 PMC: 9916911. DOI: 10.3390/ijms24032582.

Long non-coding RNA ncRuPAR regulates gastric cancer cell proliferation and apoptosis via phosphoinositide 3-kinase/protein kinase B signaling.

Xu R, Yu J, Song S, Sun D, Xiu L, Xu J Int J Med Sci. 2022; 19(13):1835-1846.

PMID: 36438913 PMC: 9682512. DOI: 10.7150/ijms.76664.

References

Madamanchi N, Hu Z, Li F, Horaist C, Moon S, Patterson C . A noncoding RNA regulates human protease-activated receptor-1 gene during embryogenesis. Biochim Biophys Acta. 2002; 1576(3):237-45. DOI: 10.1016/s0167-4781(02)00308-1. View

Yang F, Bi J, Xue X, Zheng L, Zhi K, Hua J . Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. FEBS J. 2012; 279(17):3159-65. DOI: 10.1111/j.1742-4658.2012.08694.x. View

Barbareschi M, Maisonneuve P, Aldovini D, Cangi M, Pecciarini L, Mauri F . High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer. 2003; 98(3):474-83. DOI: 10.1002/cncr.11515. View

Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, GINZBURG Y, Reich R . Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med. 1998; 4(8):909-14. DOI: 10.1038/nm0898-909. View

Sun W, Wu Y, Yu X, Liu Y, Song H, Xia T . Decreased expression of long noncoding RNA AC096655.1-002 in gastric cancer and its clinical significance. Tumour Biol. 2013; 34(5):2697-701. DOI: 10.1007/s13277-013-0821-0. View

Daaka Y . G proteins in cancer: the prostate cancer paradigm. Sci STKE. 2004; 2004(216):re2. DOI: 10.1126/stke.2162004re2. View

Yoshimizu T, Miroglio A, Ripoche M, Gabory A, Vernucci M, Riccio A . The H19 locus acts in vivo as a tumor suppressor. Proc Natl Acad Sci U S A. 2008; 105(34):12417-22. PMC: 2527926. DOI: 10.1073/pnas.0801540105. View

Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M . Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol. 2003; 162(5):1503-13. PMC: 1851194. DOI: 10.1016/S0002-9440(10)64283-6. View

Wang W . Enhancing the treatment of metabolic syndrome with integrative medicine. J Integr Med. 2013; 11(3):153-6. DOI: 10.3736/jintegrmed2013033. View

10.

Mei D, Song H, Wang K, Lou Y, Sun W, Liu Z . Up-regulation of SUMO1 pseudogene 3 (SUMO1P3) in gastric cancer and its clinical association. Med Oncol. 2013; 30(4):709. DOI: 10.1007/s12032-013-0709-2. View

11.

Muers M . RNA: Genome-wide views of long non-coding RNAs. Nat Rev Genet. 2011; 12(11):742. DOI: 10.1038/nrg3088. View

12.

Brenner H, Rothenbacher D, Arndt V . Epidemiology of stomach cancer. Methods Mol Biol. 2008; 472:467-77. DOI: 10.1007/978-1-60327-492-0_23. View

13.

Liu D, Zhang Z, Kong C . High FOXM1 expression was associated with bladder carcinogenesis. Tumour Biol. 2013; 34(2):1131-8. DOI: 10.1007/s13277-013-0654-x. View

14.

Coughlin S . Thrombin signalling and protease-activated receptors. Nature. 2000; 407(6801):258-64. DOI: 10.1038/35025229. View

15.

Matouk I, Degroot N, Mezan S, Ayesh S, Abu-Lail R, Hochberg A . The H19 non-coding RNA is essential for human tumor growth. PLoS One. 2007; 2(9):e845. PMC: 1959184. DOI: 10.1371/journal.pone.0000845. View

16.

Sarela A, Verbeke C, Ramsdale J, Davies C, Markham A, Guillou P . Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer. 2002; 86(6):886-92. PMC: 2364160. DOI: 10.1038/sj.bjc.6600133. View

17.

Wang K, Chang H . Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43(6):904-14. PMC: 3199020. DOI: 10.1016/j.molcel.2011.08.018. View

18.

Vu T, Hung D, Wheaton V, Coughlin S . Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991; 64(6):1057-68. DOI: 10.1016/0092-8674(91)90261-v. View

19.

Huarte M, Guttman M, Feldser D, Garber M, Koziol M, Kenzelmann-Broz D . A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010; 142(3):409-19. PMC: 2956184. DOI: 10.1016/j.cell.2010.06.040. View

20.

Yin Y, Salah Z, Maoz M, Even Ram S, Ochayon S, Neufeld G . Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation. FASEB J. 2003; 17(2):163-74. DOI: 10.1096/fj.02-0316com. View